| CAS NO: | 1532533-78-0 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
Physicochemical info |
CAS#: 1532533-78-0 (HCl) Chemical Formula: C31H25ClF3N5O3 Exact Mass: 607.1598 Molecular Weight: 608.01 |
|---|---|
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Technical Information | Synonym: TGR-1202 hydrochloride; TGR 1202 hydrochloride; TGR1202 hydrochloride; TGR-1202 HCl; TGR 1202 HCl; TGR1202 HCl; Chemical Name: 2-[(1S)-1-[4-Amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one hydrochloride InChi Key: QGVUVMVWYWMZIR-NTISSMGPSA-N InChi Code: InChI=1S/C31H24F3N5O3.ClH/c1-15(2)41-24-9-7-18(12-22(24)34)27-26-30(35)36-14-37-31(26)39(38-27)16(3)29-25(17-5-4-6-19(32)11-17)28(40)21-13-20(33)8-10-23(21)42-29;/h4-16H,1-3H3,(H2,35,36,37);1H/t16-;/m0./s1 SMILES Code: O=C1C(C2=CC=CC(F)=C2)=C([C@@H](N3N=C(C4=CC=C(OC(C)C)C(F)=C4)C5=C(N)N=CN=C53)C)OC6=C1C=C(F)C=C6.[H]Cl |
In Vitro |
In vitroActivity: TGR-1202 causes a half-maximal inhibition of human whole blood CD19 cell proliferation between 100-300 nM. In human lymphoma and leukemia cell lines, TGR-1202 (10 nM-100 μM) inhibits phosphorylated AKT at Ser473 in a concentration-dependent manner. TGR-1202 and carfilzomib synergistically kill blood cancer cells through disrupting the 4E-BP1-eIF4F-c-Myc axis. TGR-1202 and carfilzomib in combination synergistically and selectively silence the c-Myc and E2F transcription programs. TGR-1202 (15-50 μM) potently represses the expression of c-Myc in the DLBCL cell line LY7, and is uniquely characterized with structural features suitable for targeting CK1ε in lymphoma cells. Kinase Assay: Umbralisib (TGR-1202) is a novel PI3Kδ inhibitor, with IC50 and EC50 of 22.2 nM and 24.3 nM, respectively; Umbralisib (TGR-1202) is also active against CK1ε, with an EC50 value of 6.0 μM. Cell Assay: Multiple Myeloma resistant (MM-1R) or sensitive (MM-1S) cells are incubated with desired concentrations of RP5264. Growth is assessed after 96 h by a MTT assay. |
In Vivo |
In a subcutaneous xenograft model of T-cell acute lymphoblastic leukemia (T-ALL) in NOD/SCID mice using the MOLT-4 cell line, TGR-1202 (150 mg/kg, daily p.o.) significantly shrinks the tumors by day 25 |
Animal model |
Female Balb/c mice |
Formulation & Dosage |
12.5, 25, 50 mg/kg; oral gavage |
References |
Blood. 2017 Jan 5;129(1):88-99; Swaroop Vakkalanka, et al. AACR Poster. 2012, Poster3741. |
m.cnreagent.com
